Polishing the Therapy of Onychomycosis Induced by Spp.: Amphotericin B-Loaded Nail Lacquer

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Jun 2

PMID 34073997

Citations 6

Authors

Aleph M S Souza

Renato C A Ribeiro

Gleyse K L O Pinheiro

Francisco I Pinheiro

Wogenes N Oliveira

Luanda B F C Souza

Andre L Silva

Lucas Amaral-Machado

Everton N Alencar

Guilherme M Chaves

Eryvaldo S T Egito

Affiliations

Soon will be listed here.

Abstract

Onychomycosis induced by spp. has several limitations regarding its treatment. Nail lacquers display the potential to overcome these drawbacks by providing therapeutic compliance and increasing local drug bioavailability. Thus, this work aimed to produce a nail lacquer loaded with Amphotericin B (AmB) and evaluate its performance. The AmB-loaded nail lacquer was produced and preliminarily characterized. An AmB quantification method was developed. Stability, drug release, permeability and anti- activity assays were conducted. The analytical method validation met the acceptance criteria. The drug loading efficiency was 100% (0.02 mg/g of total product), whereas the AmB stability was limited to ≅7 days (≅90% remaining). The nail lacquer displayed a drying time of 187 s, non-volatile content of around 20%, water-resistance of approximately 2% of weight loss and satisfactory in vitro adhesion. Moreover, the in vitro antifungal activity against different spp. strains was confirmed. The AmB release and the ex vivo permeability studies revealed that AmB leaves the lacquer and permeates the nail matrix in 47.76 ± 0.07% over 24 h. In conclusion, AmB-loaded nail lacquer shows itself as a promising extemporaneous dosage form with remarkable anti- activity related to onychomycosis.

Citing Articles

Contemporary Techniques and Potential Transungual Drug Delivery Nanosystems for The Treatment of Onychomycosis.

Abd-Elsalam W, Abouelatta S AAPS PharmSciTech. 2023; 24(6):150.

PMID: 37421509 DOI: 10.1208/s12249-023-02603-x.

Novel and Investigational Treatments for Onychomycosis.

Gregoriou S, Kyriazopoulou M, Tsiogka A, Rigopoulos D J Fungi (Basel). 2022; 8(10).

PMID: 36294644 PMC: 9604567. DOI: 10.3390/jof8101079.

Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.

Monti D, Tampucci S, Paganini V, Burgalassi S, Chetoni P, Galvan J Life (Basel). 2022; 12(6).

PMID: 35743832 PMC: 9225083. DOI: 10.3390/life12060801.

Printing Drugs onto Nails for Effective Treatment of Onychomycosis.

Pollard T, Bonetti M, Day A, Gaisford S, Orlu M, Basit A Pharmaceutics. 2022; 14(2).

PMID: 35214182 PMC: 8879958. DOI: 10.3390/pharmaceutics14020448.

In Silico Drug Screening Based Development of Novel Formulations for Onychomycosis Management.

Fatima M, Monawwar S, Mohapatra S, Santosh Alex T, Ahmed A, Taleuzzaman M Gels. 2021; 7(4).

PMID: 34842710 PMC: 8628710. DOI: 10.3390/gels7040221.

References

Westerberg D, Voyack M . Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013; 88(11):762-70. View

Monod M, Mehul B . Recent Findings in Onychomycosis and Their Application for Appropriate Treatment. J Fungi (Basel). 2019; 5(1). PMC: 6463057. DOI: 10.3390/jof5010020. View

Thomas J, Jacobson G, Narkowicz C, Peterson G, Burnet H, Sharpe C . Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010; 35(5):497-519. DOI: 10.1111/j.1365-2710.2009.01107.x. View

Sleven R, Lanckacker E, Delputte P, Maes L, Cos P . Evaluation of topical antifungal products in an in vitro onychomycosis model. Mycoses. 2016; 59(5):327-30. DOI: 10.1111/myc.12475. View

Vlahovic T . Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes. Clin Podiatr Med Surg. 2016; 33(3):305-18. DOI: 10.1016/j.cpm.2016.02.001. View

Tabara K, Szewczyk A, Bienias W, Wojciechowska A, Pastuszka M, Oszukowska M . Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol. 2015; 32(1):40-5. PMC: 4360009. DOI: 10.5114/pdia.2014.40968. View

Nkondjo Minkoumou S, Fabrizi V, Papini M . Onychomycosis in Cameroon: a clinical and epidemiological study among dermatological patients. Int J Dermatol. 2012; 51(12):1474-7. DOI: 10.1111/j.1365-4632.2012.05509.x. View

Barot B, Parejiya P, Patel H, Mehta D, Shelat P . Drug delivery to the nail: therapeutic options and challenges for onychomycosis. Crit Rev Ther Drug Carrier Syst. 2014; 31(6):459-94. DOI: 10.1615/critrevtherdrugcarriersyst.2014008464. View

Bhatta A, Keyal U, Huang X, Zhao J . Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis. J Am Acad Dermatol. 2016; 74(5):916-23. DOI: 10.1016/j.jaad.2015.12.002. View

10.

Pittrof F, Gerhards J, Erni W, Klecak G . Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992; 17 Suppl 1:26-8. DOI: 10.1111/j.1365-2230.1992.tb00273.x. View

11.

Lipner S, Scher R . Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol. 2018; 80(4):835-851. DOI: 10.1016/j.jaad.2018.03.062. View

12.

Seck M, Ndiaye D, Diongue K, Ndiaye M, Badiane A, Sow D . [Mycological profile of onychomycosis in Dakar (Senegal)]. J Mycol Med. 2014; 24(2):124-8. DOI: 10.1016/j.mycmed.2014.02.002. View

13.

Geizhals S, Cooley V, Lipner S . Diagnostic testing for onychomycosis: A retrospective study over 17 years. J Am Acad Dermatol. 2019; 83(1):239-241. DOI: 10.1016/j.jaad.2019.12.019. View

14.

Khattab A, Shalaby S . Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis. AAPS PharmSciTech. 2017; 19(3):1048-1060. DOI: 10.1208/s12249-017-0917-8. View

15.

Halim I, El Kadioui F, Soussi Abdallaoui M . [Onychomycosis in Casablanca (Morocco)]. J Mycol Med. 2013; 23(1):9-14. DOI: 10.1016/j.mycmed.2012.10.002. View

16.

Torrado J, Espada R, Ballesteros M, Torrado-Santiago S . Amphotericin B formulations and drug targeting. J Pharm Sci. 2007; 97(7):2405-25. DOI: 10.1002/jps.21179. View

17.

Gupta A, Paquet M, Simpson F . Therapies for the treatment of onychomycosis. Clin Dermatol. 2013; 31(5):544-54. DOI: 10.1016/j.clindermatol.2013.06.011. View

18.

Manzano-Gayosso P, Mendez-Tovar L, Arenas R, Hernandez-Hernandez F, Millan-Chiu B, Torres-Rodriguez J . [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds]. Rev Iberoam Micol. 2010; 28(1):32-5. DOI: 10.1016/j.riam.2010.11.002. View

19.

Silva K, Junior F, Farias I, Silva A, Neto J, Souza L . Stationary cuvette: a new approach to obtaining analytical curves by UV-VIS spectrophotometry. Phytochem Anal. 2009; 20(4):265-71. DOI: 10.1002/pca.1122. View

20.

Gupta A, Simpson F . Diagnosing onychomycosis. Clin Dermatol. 2013; 31(5):540-3. DOI: 10.1016/j.clindermatol.2013.06.009. View